3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
250
Leukemia
186
Leukemia, Myeloid, Acute
103
Myelodysplastic Syndromes
78
Lymphoma
73
Burkitt Lymphoma
69
Leukemia, Lymphocytic, Chronic, B-Cell
49
Leukemia, Myeloid, Accelerated Phase
45
Lymphoma, Non-Hodgkin
44
Hodgkin Disease
41
Lymphoma, Large B-Cell, Diffuse
40
Leukemia, Myeloid, Chronic-Phase
39
Graft vs Host Disease
39
Congenital Abnormalities
39
Myeloproliferative Disorders
38
Blast Crisis
38
Lymphoma, Follicular
37
Leukemia, Myelomonocytic, Chronic
37
Multiple Myeloma
35
Leukemia, Biphenotypic, Acute
35
Lymphoma, Mantle-Cell
34
Lymphoma, Large-Cell, Immunoblastic
31
Lymphoma, B-Cell, Marginal Zone
31
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
30
Recurrence
29
Primary Myelofibrosis
25
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
25
Anemia, Refractory, with Excess of Blasts
24
Neoplasms, Plasma Cell
23
Hematologic Neoplasms
23
Interventions
glucarpidase
2
ripretinib
1
pevonedistat
1
gamma-Glutamyl Hydrolase
1
belinostat
1
Rituximab
1
Methotrexate
1
Leucovorin
1
Lenalidomide
1
Cyclophosphamide
1
Carboxypeptidases
1
Bendamustine Hydrochloride
1
Azacitidine
1
ARQ 197
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Renal Insufficiency
×
Methotrexate
×
Other hematologic neoplasm
×
Clear all
NCT00634504
2022-06-06
LVPK
BTG International Inc.
Phase 1
Completed
20 enrolled
9 charts